DCT

Curebase Celebrates Year of Growth, Organizational Maturity

Retrieved on: 
Wednesday, January 4, 2023
Lviv, Engineering, Patient, Clinical trial, SAN, DCTS, Partnership, Growth, DTA, FDA, Single-frequency network, Neurodegeneration, Publication, VPS, DCT, Gilead Sciences, Software, Physician, RWD, Research, Pharmaceutical industry, Medical device, Management

SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, capped off a successful 2022 with continued growth, maturity, and expansion of its footprint in the decentralized clinical trials (DCT) market.

Key Points: 
  • Curebase was founded in 2017, by CEO Tom Lemberg, to make participation in clinical trials available to any patient, regardless of location.
  • Among the major highlights, accomplishments, and milestones for Curebase in 2022 are:
    The company strengthened its advisory board by naming several industry veterans to the panel.
  • In February, Curebase added Dr. Aaron Kamauu, an industry-leading expert in real-world data (RWD), and Dr. Amir Lahav, an innovator in artificial intelligence/machine learning digital biomarker development for neurodegenerative diseases.
  • At Curebase, our mission is to bring quality medical innovations to patients faster and improve human well-being through more efficient clinical studies.

Sporty and Dynamic: GAC MOTOR EMPOW Sedan Launched in UAE

Retrieved on: 
Tuesday, December 27, 2022
F1, Torque, Gumball, GAC, Carbon, EmPower (aircraft power adapter), DCT, Gulf of Alaska

GUANGZHOU, China, Dec. 27, 2022 /PRNewswire/ -- On December 21, 2022, GAC MOTOR UAE hosted the brand's first official launch ceremony for the EMPOW, a unique, sporty sedan that represents a bold new era for the Chinese auto maker.

Key Points: 
  • GUANGZHOU, China, Dec. 27, 2022 /PRNewswire/ -- On December 21, 2022, GAC MOTOR UAE hosted the brand's first official launch ceremony for the EMPOW, a unique, sporty sedan that represents a bold new era for the Chinese auto maker.
  • EMPOW is now the latest model to be added to the GAC MOTOR's overseas lineup.
  • GAC MOTOR raced the EMPOW in the world-famous supercar attraction in Dubai, the Gumball Rally 3000.
  • "UAE is one of GAC MOTOR's most important markets in Middle East," said Zeng Hebin, General Manager of GAC MOTOR.

Insights on the Virtual Clinical Trials Global Market to 2027 - Key Players Include Dassault Systemes, Medable, Science 37 and THREAD

Retrieved on: 
Thursday, December 22, 2022
EMA, Clinical trial, Patient, EPRO, Cros, Medicine, Center for Drug Evaluation and Research, Medidata Solutions, European Medicines Agency, Drug development, AI, Growth, Science, COVID-19, Risk, HSA, ERT, Guest appearance, Medicines and Healthcare products Regulatory Agency, FDA, Human, CDE, Heads of Medicines Agencies, Dassault Systèmes, Accenture, DCT, Infection, Research, Artificial intelligence, MHRA, Medical device, Pharmaceutical industry, Medical imaging, IQVIA

The virtual clinical trials market is one of the innovative approaches for traditional clinical trials, through remote monitoring and more patient-centric approaches.

Key Points: 
  • The virtual clinical trials market is one of the innovative approaches for traditional clinical trials, through remote monitoring and more patient-centric approaches.
  • The COVID-19 pandemic is the significant factor that shifted the traditional clinical trials approach to the virtual clinical trials market.
  • The market players and the companies pioneer in clinical trials activities understand that decentralization in clinical trials is the future of the clinical trials space.
  • THREAD offers a unique, innovative, and highly advanced decentralized clinical trial platform in the virtual clinical trials market.

Syneos Health Extends Partnership with Medable

Retrieved on: 
Tuesday, December 13, 2022
Patient, Clinical trial, Health, Partnership, DCT, Culture, Environment, Syneos Health, DCTS, Pharmaceutical industry, Healthcare

Together, Syneos Health and Medable will continue to reduce site and patient burden, improve enrollment and retention and increase patient access and diversity through innovative decentralized clinical trial (DCT) solutions.

Key Points: 
  • Together, Syneos Health and Medable will continue to reduce site and patient burden, improve enrollment and retention and increase patient access and diversity through innovative decentralized clinical trial (DCT) solutions.
  • Syneos Health first partnered with Medable in April 2021.
  • Notably, over the past 18 months, Syneos Health and Medable have collaborated on more than 15 clinical trials with the aim of reaching 21,000 patients across multiple therapeutic areas.
  • Both Medable and Syneos Health envision a near future where every life sciences company has the tools they need to revolutionize human health by expanding access to clinical trials through the use of technology,” said Dr. Michelle Longmire, Medable co-founder and CEO.

Veristat Presents Integrated, Customized DCT Solutions at the DTRA Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Research, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, Innovation, DCTS, EVP, DCT, Patient, Degenerative disease, Decentralized Trials & Research Alliance, Canavan disease, Drug development, COVID-19, Clinical trial, DTRA, Organization, Pharmaceutical industry

Offering integrated solutions for the implementation of decentralized clinical trials (DCTs) , Veristat presented the advantages of its flexible and fully customized service delivery model at the Decentralized Trials Research Alliance (DTRA) annual meeting, which took place last month in Boston.

Key Points: 
  • Offering integrated solutions for the implementation of decentralized clinical trials (DCTs) , Veristat presented the advantages of its flexible and fully customized service delivery model at the Decentralized Trials Research Alliance (DTRA) annual meeting, which took place last month in Boston.
  • "DTRAs annual conference provided the opportunity for our team to present our DCT solutions to organizations developing novel therapies which target complex and rare diseases," said Shaheen Limbada, EVP of Innovation and Strategy at Veristat.
  • In addition, Veristat has introduced its own virtual site, inclusive of patient accrual, call center intake, and protocol visit completion.
  • With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Everest Group Names Medidata a ‘Leader’ and ‘Star Performer’ in Decentralized Clinical Trial Platforms

Retrieved on: 
Tuesday, December 13, 2022
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Security, Other Technology, Research, Science, Clinical Trials, Cloud, SOLIDWORKS, Clinical trial, DCTS, CATIA, DCT, DELMIA, Learning, Patient, Dassault Group, Research, 3D, Cros, Investment, SIMULIA, Annual report, Euronext Paris, Pharmaceutical industry, Medidata Solutions, ENOVIA, Compass, GEOVIA, BIOVIA

Medidata , a Dassault Systmes company, has been named a Leader and Star Performer in the Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023 by Everest Group.

Key Points: 
  • Medidata , a Dassault Systmes company, has been named a Leader and Star Performer in the Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023 by Everest Group.
  • The annual report evaluates decentralized clinical trial (DCT) products from 24 companies based on vision, capability, and market impact.
  • Its solution is highly recognized for governance, security, and compliance by clients, said Chunky Satija, vice president at Everest Group.
  • Recognition from Everest as both a Leader and Star Performer validates the success we have gained with our sponsors and CROs.

Reuters Recognizes Medable for Innovation, Industry Impact at Pharma Awards USA 2022

Retrieved on: 
Monday, December 12, 2022
Data Management, Health, Technology, Software, Clinical Trials, Biotechnology, Innovation, ROI, Clinical trial, Name, Drug, DCT, Patient, Research, Tufts Center for the Study of Drug Development, Mount Everest, Multimedia, Reuters, Drug development, Movement, GSK, Microsoft Most Valuable Professional, Traction, IDC, Organization, Pharmaceutical industry, Fine chemical

Medable, Inc. , the industry-leading technology platform for unified clinical trials, won the Most Valuable Clinical Technology Award and the Health Entrepreneur Award at the Reuters Pharma Awards USA 2022 .

Key Points: 
  • Medable, Inc. , the industry-leading technology platform for unified clinical trials, won the Most Valuable Clinical Technology Award and the Health Entrepreneur Award at the Reuters Pharma Awards USA 2022 .
  • View the full release here: https://www.businesswire.com/news/home/20221212005274/en/
    Reuters Recognizes Medable for Innovation & Industry Impact at Pharma Awards USA 2022 (Graphic: Business Wire)
    These awards highlight the importance of our mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies.
  • We are honored to be recognized among such powerhouse organizations in our industry, said Michelle Longmire, CEO and Co-founder of Medable.
  • Reuters Pharma USA 2022 winners in other categories included Medable partner GSK , for Most Valuable Digital Patient Engagement, as well as several other household names in the pharmaceutical industry.

Emmes Hires Ching Tian in New Leadership Role to Accelerate Innovation

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Biostatistics, Federation, PPD, Data management, Novartis, DCT, Contract research organization, Public health, Hangzhou Dianzi University, Vacuum, Research, University, Multimedia, Health, Fine chemical, Pharmaceutical industry, Management, EMMS International

Emmes Chief ExecutiveOfficer Dr. Christine Dingivan said, "Ching brings a wealth of data and digital experience, which will be immediately useful as we accelerate our transition to decentralized trials.

Key Points: 
  • Emmes Chief ExecutiveOfficer Dr. Christine Dingivan said, "Ching brings a wealth of data and digital experience, which will be immediately useful as we accelerate our transition to decentralized trials.
  • What attracted me to Emmes were Dr. Dingivan's vision of Emmes as a tech-enabled CRO, the company's roots in biostatistics, its 45-year history and science-based, high-quality clinical research reputation.
  • I'm very impressed with what the Emmes team has accomplished, and I'm excited to help lead the next phase of innovation," Tian added.
  • She added, "Ching is a visionary leader with unmatched drive for innovation, which makes her a perfect fit for Emmes as we continue our accelerated global growth strategy."

Emmes Hires Ching Tian in New Leadership Role to Accelerate Innovation

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Biostatistics, Federation, PPD, Data management, Novartis, DCT, Contract research organization, Public health, Hangzhou Dianzi University, Vacuum, Research, University, Health, Fine chemical, Pharmaceutical industry, Management, EMMS International

ROCKVILLE, Md., Dec. 14, 2022 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Ching Tian has joined the company as chief innovation officer.

Key Points: 
  • ROCKVILLE, Md., Dec. 14, 2022 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Ching Tian has joined the company as chief innovation officer.
  • Emmes Chief ExecutiveOfficer Dr. Christine Dingivan said, "Ching brings a wealth of data and digital experience, which will be immediately useful as we accelerate our transition to decentralized trials.
  • What attracted me to Emmes were Dr. Dingivan's vision of Emmes as a tech-enabled CRO, the company's roots in biostatistics, its 45-year history and science-based, high-quality clinical research reputation.
  • I'm very impressed with what the Emmes team has accomplished, and I'm excited to help lead the next phase of innovation," Tian added.

Curebase Releases Diagnostic Offering that Delivers First All-Inclusive Package of Software and Services Needed to Fully Execute Diagnostic Studies

Retrieved on: 
Tuesday, December 13, 2022
Storm, Clinical trial, Colorectal cancer, DCT, Health equity, Physician, Pi, CRC, Patient, Telehealth, SAN, Liquid biopsy, Software, Research, Pharmaceutical industry, Medical device

SAN FRANCISCO, Dec. 13, 2022 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, today announced the release of an integrated, plug-and-play software and full trial services offering that allows sponsors of diagnostic studies to accelerate enrollment and launch their trials more quickly, as the sole execution partner. 

Key Points: 
  • The new Curebase offering is the first one-stop-shop, flexible software and service package for the diagnostics market.
  • "This package fills a huge need in the diagnostic study market by efficiently getting studies started and finished through a unified approach."
  • Curebase has extensive experience in diagnostic research, running roughly 30 studies since 2020 and consenting more than 10,000 patients.
  • The company has used this experience to design and execute flexible study models through this plug-and-play diagnostics package.